Search Results - "LAMERZ, R"

Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update by Duffy, M.J., Lamerz, R., Haglund, C., Nicolini, A., Kalousová, M., Holubec, L., Sturgeon, C.

“…Biomarkers currently play an important role in the detection and management of patients with several different types of gastrointestinal cancer, especially…”
Get full text

Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report by Duffy, M.J., Sturgeon, C., Lamerz, R., Haglund, C., Holubec, V.L., Klapdor, R., Nicolini, A., Topolcan, O., Heinemann, V.

“…Pancreatic ductal adenocarcinoma is one of the most difficult malignancies to diagnose and treat. The aim of this article is to review how tumor markers can…”
Get full text

Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use by Duffy, M.J, van Dalen, A, Haglund, C, Hansson, L, Holinski-Feder, E, Klapdor, R, Lamerz, R, Peltomaki, P, Sturgeon, C, Topolcan, O

“…Abstract The aim of this article is to present updated guidelines for the use of serum, tissue and faecal markers in colorectal cancer (CRC). Lack of…”
Get full text

Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines by Duffy, M.J, van Dalen, A, Haglund, C, Hansson, L, Klapdor, R, Lamerz, R, Nilsson, O, Sturgeon, C, Topolcan, O

“…In recent years, numerous serum and cell/tissue-based markers have been described for colorectal cancer (CRC). The aim of this article was to provide…”
Get full text

Late relapse of germ cell tumors after cisplatin-based chemotherapy by Gerl, A., Clemm, C., Schmeller, N., Hentrich, M., Lamerz, R., Wilmanns, W.

“…Background: Sparse data are available with regard to the incidence, clinical characteristics, therapeutic management and prognosis of male patients with germ…”
Get full text

Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer by Reiter, W, Stieber, P, Reuter, C, Nagel, D, Lau-Werner, U, Lamerz, R

“…Carcinoembrionic Antigen (CEA) and carbohydrate antigen 19-9 (CA 19-9) are the most commonly used tumor-associated antigens in the management of patients with…”
Get more information

997 RETROSPECTIVE ANALYSIS OF 191 PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA TREATED WITH TRANSARTERIAL CHEMOEMBOLISATION (TACE): VALIDATION OF THE ESTABLISHED AND CONSTRUCTION OF AN IMPROVED HCC-STAGING-SYSTEM by op den Winkel, M, Nagel, D, op den Winkel, P, Sappl, J, Straub, G, Lamerz, R, Zech, C, Stieber, P, Kolligs, F.T

Get full text

MRI gadolinium enhancement of bone marrow : age-related changes in normals and in diffuse neoplastic infiltration by BAUR, A, STÄBLER, A, BARTL, R, LAMERZ, R, SCHEIDLER, J, REISER, M

“…To quantify gadolinium-related enhancement in the bone marrow of the spine in normals and in patients with homogeneous diffuse malignant bone marrow…”
Get full text

Changes of Thymidine Kinase (TK) During Adjuvant and Palliative Chemotherapy by TOPOLCAN, O, HOLUBEC, L. JR, FINEK, J, STIEBER, P, HOLDENRIEDER, S, LAMERZ, R, HOLUBEC SEN, L, SVOBODOVA, S, VISOKAI, V, LIPSKA, L

“…Thymidine kinase is involved in nucleic acid synthesis and is, therefore, considered to be an important proliferation tumor marker. For this reason, we…”
Get full text

Are serial CA 19-9 kinetics helpful in predicting survival in patients with advanced or metastatic pancreatic cancer treated with gemcitabine and cisplatin? by Stemmler, J, Stieber, P, Szymala, A M, Schalhorn, A, Schermuly, M M, Wilkowski, R, Helmberger, T, Lamerz, R, Stoffregen, C, Niebler, K, Garbrecht, M, Heinemann, V

“…Serial kinetics of serum CA 19-9 levels have been reported to reflect response and survival in patients with pancreatic cancer undergoing surgery,…”
Get more information

Diagnosis and multimodal therapy for hepatocellular carcinoma by Kolligs, F T, Hoffmann, R-T, op den Winkel, M, Bruns, C J, Herrmann, K, Jakobs, T F, Lamerz, R, Trumm, C, Zech, C J, Wilkowski, R, Graeb, C

“…Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death in the world. The majority of HCCs develops on the basis of a chronic liver…”
Get more information

MULTIPLE MYELOMA UPDATE IN RISK CONSIDERATION, DIAGNOSIS, AND THERAPY, WITH TRENDS AND PERSPECTIVES by Lamerz, R

“…An updated review is presented on the oncogenomics/ genomics (e.g. hyperdiploidy, specific translocations such as t(11; 14), t(4; 14), t(14; 16), activation of…”
Get full text

Clinical Relevance of Tumor Markers for the Control of Chemotherapy by FINEK, J, HOLUBEC, L. JR, VISOKAI, V, HELMICHOVA, E, TOPOLCAN, O, SAL VET, J, PIKNER, R, HOLDENRIEDER, S, STIEBER, P, LAMERZ, R, HOLUBEC SEN, L, SVOBODOVA, S

“…This presentation is based on our experience with tumor marker monitoring of surgery therapy and chemotherapy effects. The control of chemotherapy is one of…”
Get full text

Hepatotoxicity following desflurane anesthesia by Berghaus, Thomas M., Baron, Andreas, Geier, Andreas, Lamerz, Rolf, Paumgartner, Gustav, Conzen, Peter

Get full text

Role of tumour markers, cytogenetics by LAMERZ, R

“…A review is presented on the role of conventional and molecular tumour markers (TM) in diagnosis and monitoring of patients with biliopancreatic malignancies…”
Get full text

Improvement of histological biopsy diagnosis of hepatocellular carcinoma by genomic biomarkers? by Lamerz, Rolf

Get more information

Clinical utility of biochemical markers in colorectal cancer by Duffy, M.J, van Dalen, A, Haglund, C, Hansson, L, Klapdor, R, Lamerz, R, Nilsson, O, Sturgeon, C, Topolcan, O

Get full text

Prognosis after salvage treatment for unselected male patients with germ cell tumours by GERL, A, CLEMM, C, SCHMELLER, N, HARTENSTEIN, R, LAMERZ, R, WILMANNS, W

“…Long-term outcome of salvage treatment was reviewed in 67 unselected male patients relapsing during or after their primary cisplatin-based chemotherapy for…”
Get full text

25 YEARS OF MULTIPLE MYELOMA: A HISTORICAL UPDATE IN DIAGNOSIS, THERAPY, TRENDS AND PERSPECTIVES by Lamerz, R

“…Multiple myeloma (MM) is a malignant plasma cell disorder with an incicence of about 4.3/100,000 in an age-adjusted US or Western population accounting for 10%…”
Get full text

Outcome analysis after post-chemotherapy surgery in patients with non-seminomatous germ cell tumours by Gerl, A, Clemm, C, Schmeller, N, Dienemann, H, Lamerz, R, Kriegmair, M, Wilmanns, W

“…The goal of the study was to analyse long-term outcome after post-chemotherapy surgery in male patients with non-seminomatous germ cell tumours (NSGCT). We…”
Get more information